100% of Cancer Patients in Remission After Monoclonal Antibody Trial: ‘Tumors just vanished’

Contact Your Elected Officials
EpochTV Header

Researchers just published a new study that, for the first time, found a treatment that completely removed rectal cancer in every patient that participated—meaning that every single patient in the study is in remission, with no chemo, no radiation, and no surgery.

And even though the study was small, the results are not only heartening, but also, according to the lead researcher, they open up a potential new corridor for fighting cancer—which they will be expanding quickly to treat stomach, pancreatic, as well as bladder cancer.

Furthermore, the therapy they’re testing (monoclonal antibodies) has none of the toxic side effects of the other treatments currently being used.


🔵 Full Trial Study:


🔵 Study Analysis:


🔵 Epoch TV:


Watch Full Video on EpochTV

The Epoch Times Header

Cancer Trial Using Monoclonal Antibody Finds Remission in Every Patient: Report

cancer trial has reportedly become the first in the world to completely remove the disease in every patient, according to a study published on June 5 in The New England Journal of Medicine.

The study, “PD-1 Blockade in Mismatch Repair—Deficient, Locally Advanced Rectal Cancer,” was conducted among 12 rectal cancer patients, all of whom had a “clinical complete response,” according to the authors, led by Dr. Andrea Cercek of the Memorial Sloan Kettering Cancer Center in New York.

Doctors have been unable to see any evidence of tumors among the patients when using magnetic resonance imaging, fludeoxyglucose F 18 injections, physical examinations, or endoscopic evaluations, according to researchers.

The patients also continued to show no signs of cancer during follow-ups ranging from six months to 25 months and haven’t had to undergo surgery or receive radiation and chemotherapy.

“No adverse events of grade 3 or higher have been reported,” the study authors noted.

Specifically, the rectal cancer patients were given dostarlimab, a monoclonal antibody, every three weeks for six months. The patients had mismatch repair-deficient stage two or three rectal adenocarcinomas, a type of cancer.

The median age of the patients enrolled was 54 years old and 62 percent of them were women.

Typically, such cancer patients would have needed to undergo often debilitating treatments such as chemotherapy, radiation, or surgery, and in extreme cases be fitted with colostomy bags.

However, after taking dostarlimab, which is sold under the brand name Jemperli, no cases of progression or recurrence were reported in the patients who underwent the study.

Dostarlimab is already approved by the U.S. Food and Drug Administration for use in the treatment of adult patients with mismatch repair-deficient recurrent or advanced solid tumors. Rectal cancer is an off-label use, according to Medscape.

According to drugs.com, the cost of Jemperli intravenous solution (500 milligrams/10 milliliters) is around $11,201 for a supply of 10 milliliters.

By Katabella Roberts

Read Full Article on TheEpochTimes.com

Biden Doesn't Have Americans Best Interest At Heart